Logo image of ALTME.PA

TME PHARMA NV (ALTME.PA) Stock Price, Forecast & Analysis

Europe - Euronext Paris - EPA:ALTME - NL0015000YE1 - Common Stock

0.0614 EUR
+0 (+0.16%)
Last: 1/16/2026, 7:00:00 PM

ALTME.PA Key Statistics, Chart & Performance

Key Statistics
Market Cap5.78M
Revenue(TTM)27.00K
Net Income(TTM)-4.58M
Shares94.19M
Float94.15M
52 Week High0.15
52 Week Low0.05
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.08
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPO2018-09-10
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
ALTME.PA short term performance overview.The bars show the price performance of ALTME.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30 -40

ALTME.PA long term performance overview.The bars show the price performance of ALTME.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ALTME.PA is 0.0614 EUR. In the past month the price increased by 2.33%. In the past year, price decreased by -15.08%.

TME PHARMA NV / ALTME Daily stock chart

ALTME.PA Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to ALTME.PA. When comparing the yearly performance of all stocks, ALTME.PA is a bad performer in the overall market: 94.52% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ALTME.PA Financial Highlights

Over the last trailing twelve months ALTME.PA reported a non-GAAP Earnings per Share(EPS) of -0.08. The EPS increased by 86.56% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -199.56%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%81.23%
Sales Q2Q%N/A
EPS 1Y (TTM)86.56%
Revenue 1Y (TTM)N/A

ALTME.PA Forecast & Estimates

9 analysts have analysed ALTME.PA and the average price target is 0.11 EUR. This implies a price increase of 71.11% is expected in the next year compared to the current price of 0.0614.

For the next year, analysts expect an EPS growth of 89.47% and a revenue growth -100% for ALTME.PA


Analysts
Analysts84.44
Price Target0.11 (79.15%)
EPS Next Y89.47%
Revenue Next Year-100%

ALTME.PA Ownership

Ownership
Inst Owners3.98%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A

ALTME.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
1AE.DE ARGENX SE 64.92 42.73B
ARGX.BR ARGENX SE 64.88 42.70B
22UA.DE BIONTECH SE-ADR N/A 22.67B
2X1.DE ABIVAX SA N/A 7.97B
ABVX.PA ABIVAX SA N/A 7.95B
GXE.DE GALAPAGOS NV N/A 1.92B
GLPG.AS GALAPAGOS NV N/A 1.91B
IVA.PA INVENTIVA SA N/A 1.09B
6IV.DE INVENTIVA SA N/A 962.73M
NANO.PA NANOBIOTIX N/A 891.02M
5CV.DE CUREVAC NV 6.71 876.36M
PHIL.MI PHILOGEN SPA 19.12 637.43M

Related stock screener links

About ALTME.PA

Company Profile

ALTME logo image TME Pharma NV is a clinical-stage biopharmaceutical company, which focuses on therapeutics targeting the tumor microenvironment or TME. The company is headquartered in Berlin, Berlin and currently employs 12 full-time employees. The company went IPO on 2018-09-10. The firm specializes in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Its technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. their clinical programs in glioblastoma and pancreatic cancer have delivered results and further development is planned.

Company Info

TME PHARMA NV

Max-Dohrn-Str. 8-10

Berlin BERLIN DE

Employees: 12

ALTME Company Website

ALTME Investor Relations

Phone: 49307262470

TME PHARMA NV / ALTME.PA FAQ

What does TME PHARMA NV do?

TME Pharma NV is a clinical-stage biopharmaceutical company, which focuses on therapeutics targeting the tumor microenvironment or TME. The company is headquartered in Berlin, Berlin and currently employs 12 full-time employees. The company went IPO on 2018-09-10. The firm specializes in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Its technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. their clinical programs in glioblastoma and pancreatic cancer have delivered results and further development is planned.


What is the current price of ALTME stock?

The current stock price of ALTME.PA is 0.0614 EUR. The price increased by 0.16% in the last trading session.


Does ALTME stock pay dividends?

ALTME.PA does not pay a dividend.


What is the ChartMill rating of TME PHARMA NV stock?

ALTME.PA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.


What do analysts say about TME PHARMA NV (ALTME.PA) stock?

9 analysts have analysed ALTME.PA and the average price target is 0.11 EUR. This implies a price increase of 71.11% is expected in the next year compared to the current price of 0.0614.


What is the employee count for ALTME stock?

TME PHARMA NV (ALTME.PA) currently has 12 employees.